AXGN
AxoGen, Inc. (AXGN)
Healthcare • Medical Devices • $39.85 • MCap: 2,119,136,256
🌐
https://www.axogeninc.com • Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide. The company offers Avance Nerve Graft, a processed nerve allograft intended for the surgical repair of peripheral nerve discontinuities; Axoguard Nerve Connector, a coaptation aid used to align and connect severed peripheral nerve ends in a tensionless repair; and Axoguard Nerve Protector, a product used to protect and wrap damaged peripheral nerves and reinforce reconstructed nerve gaps. It also provides Axoguard HA+ Nerve Protector, a surgical implant for non-constricting protection of the peripheral nerves; Axoguard Nerve Cap, a porcine submucosa ECM product; Avive+ Soft Tissue Matrix, a multi-layer amniotic membrane allograft; and Avance Method, a technique to process Avance Nerve Graft from donated human peripheral nerve tissue. In addition, the company offers peripheral nerve tissue recovery and acquisition, and testing, as well as donor medical review and release, debridement and other processing steps, packaging, and sterilization. It provides its products to hospitals, surgery centers and military hospitals, calling on surgeons, including plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and certain oral and maxillofacial surgeons through independent in-country distributors. The company is headquartered in Alachua, Florida.
Buy Decision Core
Total Score
41
Business Quality
10
Financial Strength
18
Growth Outlook
1
Momentum
6
Price Action
Current
39.85
52W High
46.19
52W Low
11.28
Above 50DMA
42.23 (-5.65%)
Above 200DMA
32.89 (21.15%)
Relative Strength
Relative Strength
0.87
RS 3M
0.07
RS 6M
0.29
RS 9M
1.51
RS 12M
2.43
Fundamentals
Revenue Growth
0.27%
Earnings Growth
0%
ROE
-0.18%
ROA
-0.02%
Valuation
PE (Fwd)
54.71
PEG
99.04
P/B
8.65
Upside
27.42%
Risk
Beta
1.09
Short %
0.10
Risk Score
3.00
Analyst
Rating
strong_buy
Target
50.78
Beta
1.09
Analysts
0
Total Score
41
Upside
27.42%
Relative Strength
0.87
Beta
1.09
Why Buy?
- Trading above 200 DMA
- Analyst upside exceeds 15%
Key Risks
- Negative ROE
Score Breakdown
Business
10
10
Financial
18
18
Growth
1
1
Valuation
1
1
Risk
3
3
Momentum
6
6
Technical
52W High: 46.19
52W Low: 11.28
Above 50DMA: -5.65%
Above 200DMA: 21.15%
Valuation
Forward PE: 54.71
PEG: 99.04
P/B: 8.65
Upside: 27.42%
Risk
Beta: 1.09
Short Float: 0.10%
ROE: -0.18%
ROA: -0.02%